Oncocyte (IMDX) Competitors

Oncocyte logo
$1.77 -0.09 (-4.84%)
As of 03:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IMDX vs. EIKN, PROK, PRLD, BNTC, and XFOR

Should you buy Oncocyte stock or one of its competitors? Oncocyte's main competitors and comparable companies include Eikon Therapeutics (EIKN), ProKidney (PROK), Prelude Therapeutics (PRLD), Benitec Biopharma (BNTC), and X4 Pharmaceuticals (XFOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncocyte compare to Eikon Therapeutics?

Oncocyte (NASDAQ:IMDX) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Eikon Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%.

Company Net Margins Return on Equity Return on Assets
Oncocyte-2,955.63% N/A -107.52%
Eikon Therapeutics N/A N/A N/A

Oncocyte has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncocyte$4.05M14.30-$50.22M-$1.49N/A
Eikon TherapeuticsN/AN/A-$324.25M-$4.09N/A

Oncocyte presently has a consensus price target of $10.50, suggesting a potential upside of 493.22%. Eikon Therapeutics has a consensus price target of $24.67, suggesting a potential upside of 388.84%. Given Oncocyte's higher possible upside, analysts clearly believe Oncocyte is more favorable than Eikon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncocyte
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.56

55.4% of Oncocyte shares are held by institutional investors. 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Eikon Therapeutics had 11 more articles in the media than Oncocyte. MarketBeat recorded 18 mentions for Eikon Therapeutics and 7 mentions for Oncocyte. Eikon Therapeutics' average media sentiment score of 0.90 beat Oncocyte's score of 0.89 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncocyte
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Eikon Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Oncocyte and Eikon Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Oncocyte compare to ProKidney?

Oncocyte (NASDAQ:IMDX) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Oncocyte has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncocyte$4.05M14.30-$50.22M-$1.49N/A
ProKidney$890K371.96-$68.99M-$0.60N/A

In the previous week, ProKidney had 9 more articles in the media than Oncocyte. MarketBeat recorded 16 mentions for ProKidney and 7 mentions for Oncocyte. Oncocyte's average media sentiment score of 0.89 beat ProKidney's score of -0.24 indicating that Oncocyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncocyte
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ProKidney
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oncocyte has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

Oncocyte currently has a consensus target price of $10.50, suggesting a potential upside of 493.22%. ProKidney has a consensus target price of $10.00, suggesting a potential upside of 813.24%. Given ProKidney's stronger consensus rating and higher probable upside, analysts plainly believe ProKidney is more favorable than Oncocyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncocyte
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
ProKidney
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

Oncocyte has a net margin of -2,955.63% compared to ProKidney's net margin of -13,326.71%.

Company Net Margins Return on Equity Return on Assets
Oncocyte-2,955.63% N/A -107.52%
ProKidney -13,326.71%N/A -35.31%

Summary

ProKidney beats Oncocyte on 8 of the 14 factors compared between the two stocks.

How does Oncocyte compare to Prelude Therapeutics?

Oncocyte (NASDAQ:IMDX) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Oncocyte has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncocyte$4.05M14.30-$50.22M-$1.49N/A
Prelude Therapeutics$12.14M21.59-$99.50M-$0.73N/A

In the previous week, Oncocyte had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 7 mentions for Oncocyte and 5 mentions for Prelude Therapeutics. Oncocyte's average media sentiment score of 0.89 beat Prelude Therapeutics' score of -0.39 indicating that Oncocyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncocyte
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Prelude Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oncocyte currently has a consensus target price of $10.50, indicating a potential upside of 493.22%. Prelude Therapeutics has a consensus target price of $8.75, indicating a potential upside of 166.36%. Given Oncocyte's higher probable upside, equities analysts plainly believe Oncocyte is more favorable than Prelude Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncocyte
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Prelude Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Prelude Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Prelude Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncocyte-2,955.63% N/A -107.52%
Prelude Therapeutics N/A -75.35%-44.39%

Oncocyte has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Summary

Prelude Therapeutics beats Oncocyte on 9 of the 16 factors compared between the two stocks.

How does Oncocyte compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Benitec Biopharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Benitec BiopharmaN/A -28.41% -27.76%
Oncocyte -2,955.63%N/A -107.52%

Benitec Biopharma currently has a consensus price target of $21.85, indicating a potential upside of 170.81%. Oncocyte has a consensus price target of $10.50, indicating a potential upside of 493.22%. Given Oncocyte's higher possible upside, analysts plainly believe Oncocyte is more favorable than Benitec Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Benitec Biopharma
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
Oncocyte
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Benitec Biopharma had 6 more articles in the media than Oncocyte. MarketBeat recorded 13 mentions for Benitec Biopharma and 7 mentions for Oncocyte. Oncocyte's average media sentiment score of 0.89 beat Benitec Biopharma's score of 0.62 indicating that Oncocyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Benitec Biopharma
1 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Oncocyte
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Benitec Biopharma has higher earnings, but lower revenue than Oncocyte. Benitec Biopharma is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benitec BiopharmaN/AN/A-$45.55M-$1.02N/A
Oncocyte$4.05M14.30-$50.22M-$1.49N/A

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 8.0% of Benitec Biopharma shares are held by company insiders. Comparatively, 2.2% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Benitec Biopharma has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Oncocyte has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

Summary

Benitec Biopharma beats Oncocyte on 8 of the 15 factors compared between the two stocks.

How does Oncocyte compare to X4 Pharmaceuticals?

Oncocyte (NASDAQ:IMDX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Oncocyte had 5 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 7 mentions for Oncocyte and 2 mentions for X4 Pharmaceuticals. Oncocyte's average media sentiment score of 0.89 beat X4 Pharmaceuticals' score of 0.41 indicating that Oncocyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncocyte
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
X4 Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oncocyte has higher earnings, but lower revenue than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncocyte$4.05M14.30-$50.22M-$1.49N/A
X4 Pharmaceuticals$35.11M8.57-$79.20M-$0.67N/A

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oncocyte currently has a consensus target price of $10.50, indicating a potential upside of 493.22%. X4 Pharmaceuticals has a consensus target price of $11.25, indicating a potential upside of 270.68%. Given Oncocyte's higher possible upside, equities research analysts clearly believe Oncocyte is more favorable than X4 Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncocyte
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
X4 Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Oncocyte has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

X4 Pharmaceuticals has a net margin of -474.74% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncocyte-2,955.63% N/A -107.52%
X4 Pharmaceuticals -474.74%-49.62%-30.80%

Summary

Oncocyte beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Oncocyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMDX vs. The Competition

MetricOncocyteBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$57.91M$4.03B$7.73B$11.61B
Dividend YieldN/A3.62%2.46%4.43%
P/E Ratio-1.1923.9734.1629.83
Price / Sales14.3016.198.475.65
Price / CashN/A26.3721.9322.50
Price / Book-1.614.064.373.65
Net Income-$50.22M-$22.82M$3.52B$392.18M
7 Day Performance-28.34%-7.34%-5.48%-4.27%
1 Month Performance-41.20%-6.15%-4.62%-6.75%
1 Year PerformanceN/A-6.90%-1.57%-7.22%

Oncocyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMDX
Oncocyte
2.1034 of 5 stars
$1.77
-4.8%
$10.50
+493.2%
N/A$57.91M$4.05MN/A58
EIKN
Eikon Therapeutics
3.384 of 5 stars
$5.87
-0.5%
$24.67
+320.2%
N/A$346.11MN/AN/A384
PROK
ProKidney
1.8405 of 5 stars
$1.15
+0.9%
$10.00
+769.6%
-56.8%$338.60M$890KN/A231
PRLD
Prelude Therapeutics
2.4327 of 5 stars
$3.76
+4.4%
$8.75
+132.7%
+124.3%$325.60M$12.14MN/A79
BNTC
Benitec Biopharma
2.0269 of 5 stars
$9.87
+3.5%
$22.00
+122.9%
-35.1%$323.77MN/AN/A24

Related Companies and Tools


This page (NASDAQ:IMDX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners